IndianAsthmaandCOPDPatientsShowaHighSatisfactionandPreferenceforRevolizer

Source:Lung India Vol 31 Issue 4 Oct - Dec 2014

IndianAsthmaandCOPDPatients
ShowaHighSatisfactionandPreference
forRevolizer
Article concise

Drypowderinhalers (DPIs) are one of the most preferred inhalation drug delivery systems
becausetheyarebreathactuated,easytouseandcompact.Thetwoimportantfactorsthat
should be considered when prescribing an inhalation device are ease of use, patient
preference, usability and confidence since these factors are associated with efficacy and
compliance.Howeververyfewstudieshaveevaluated these parameters with DPIs. This is
the first study to assess the usability, confidence, satisfaction, and patient preference with
Revolizer(manufactured and marketed by Cipla Ltd in India) in patients with asthma and
COPDinIndia.
Thiswasanopenlabel,prospective,multicentrestudywith100participants[n=50healthy
participants, n = 45 mild asthma patients, and n = 5 mild chronic obstructive pulmonary
disease (COPD) patients]. All the participants were instructed and trained on the use of
Revolizerandthentheparticipantssubsequentlydemonstratedtheinhalationtechniqueat
twovisits.
The average time required by the participants to achieve three consecutive correct
attempts at visit 1 was 3.75 2.10 min, which significantly reduced at visit 2 (3.07
1.32 min, P < 0.01).The number of attempts required for the first correct attempt was
significantlyreducedatvisit2[2.17(1.53)atvisit1and1.82(1.11)atvisit2,P=0.005].
Withoutretraining at visit 2, 44% of the participants completed single attempt with no error
(criticalornoncritical)and74%ofparticipantscompletedsingleattemptwithnocriticalerror.
Thenumberoferrorsdecreasedfromvisit1tovisit2.
Around 93.84% participants found the Revolizer easy to operate, understand, and
rememberwhenusabilitywasassessedatboththevisits.
More than 85% participants found the Revolizer easy to use, and more than 75%
participants preferred the device. Revolizer scored high on the confidence and
satisfactionofallparticipantsatbothvisits.
Additionally, at both the visits, an average of 89.67% participants responded positively in
termsofRevolizersqualitativeattributessuchasshape,colour,portability,andlikeability,
andthecomfortwhileoperatingandhandlingthedevice.
ItwasconcludedthatRevolizerisaneasytouseandapreferreddeviceinIndianpatients
withmildasthmaandCOPD,aswellasinhealthyparticipantswithnopreviousexperienceof
usinginhalationdevices.TheparticipantsfeltconfidentandsatisfiedusingtheRevolizer.It
has the potential to become the device of choice for both patients and physicians.

Source:Lung India Vol 31 Issue 4 Oct - Dec 2014